{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:03:54Z","timestamp":1769519034387,"version":"3.49.0"},"reference-count":10,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04565\/2020"],"award-info":[{"award-number":["UIDB\/04565\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Cancer is a wide group of diseases, which was responsible for 9.6 million deaths in 2018. Cancer immunotherapies have become a reality, with the first approval for sipuleucel-T for prostate cancer therapy occurring in 2010. Listeria monocytogenes is a Gram-positive bacterium, mostly known as a food-borne pathogen, capable of causing life-threatening and often fatal infections. However, since in the majority of cases the human immune system is able to mount potent innate and adaptive immune responses that control infections by Listeria monocytogenes, the microorganism has become an attractive vector for the development of cancer vaccines. The review by Flickinger Jr., Rodeck and Snook (Vaccines 2018, 6, 48) on the use of Listeria monocytogenes as a vector for cancer immunotherapy is described and commented here.<\/jats:p>","DOI":"10.3390\/vaccines8030439","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T15:13:18Z","timestamp":1596640398000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Listeria monocytogenes as a Vector for Cancer Immunotherapy"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-274X","authenticated-orcid":false,"given":"Jorge H.","family":"Leit\u00e3o","sequence":"first","affiliation":[{"name":"IBB\u2014Institute for Bioengineering and Biosciences, Department f Bioengineering, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Av. Rovisco Pais, Torre Sul, Piso 6, 1049-001 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020). WHO Report on Cancer: Setting Priorities, Investing Wisely and Providing Care for All, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","article-title":"Cancer immunotherapy comes of age","volume":"29","author":"Topalian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in Cancer Therapy: Toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Page, A., Fusil, F., and Cosset, F.-L. (2020). Towards Physiologically and Tightly Regulated Vectored Antibody Therapies. Cancers, 12.","DOI":"10.3390\/cancers12040962"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Marhelava, K., Pilch, Z., Bajor, M., Graczyk-Jarzynka, A., and Zagozdzon, R. (2019). Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer. Cancers, 11.","DOI":"10.3390\/cancers11111756"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/JB.185.9.2683-2686.2003","article-title":"Microorganisms and Cancer: Quest for a therapy","volume":"185","author":"Chakrabarty","year":"2003","journal-title":"J. Bacteriol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4161\/bbug.1.3.10903","article-title":"Microbial-based therapy of cancer: Current progress and future prospects","volume":"1","author":"Bernardes","year":"2010","journal-title":"Bioeng. Bugs"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Roberts, B.N., Chakravarty, D., Gardner, J., Ricke, S.C., and Donaldson, J.R. (2020). Listeria monocytogenes Response to Anaerobic Environments. Pathogens, 9.","DOI":"10.3390\/pathogens9030210"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Matereke, L.T., and Okoh, A.I. (2020). Listeria monocytogenes virulence, antimicrobial resistance and environmental persistence: A Review. Pathogens, 9.","DOI":"10.3390\/pathogens9070528"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Flickinger, J.C., Rodeck, U., and Snook, A.E. (2018). Listeria monocytogenes as a vector for cancer immunotherapy: Current understanding and progress. Vaccines, 6.","DOI":"10.3390\/vaccines6030048"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:54:32Z","timestamp":1760176472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["vaccines8030439"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8030439","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]}}}